Eichenfield, Lawrence F. http://orcid.org/0000-0002-2760-0474
Liu, Jinan http://orcid.org/0009-0002-6042-5476
Marwaha, Simran http://orcid.org/0000-0003-0380-0372
Piercy, James http://orcid.org/0000-0001-7015-1021
Sturm, Daniel http://orcid.org/0009-0001-4413-8429
Anderson, Peter http://orcid.org/0000-0002-2171-8228
Funding for this research was provided by:
Incyte
Article History
Received: 21 December 2023
Accepted: 12 February 2024
First Online: 8 March 2024
Declarations
:
: Lawrence F. Eichenfield has served as an investigator, consultant, speaker, or data safety monitoring board member for AbbVie, Amgen, Arcutis, Aslan, Bristol Myers Squibb, Castle, Dermavant, Eli Lilly, Forte Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Otsuka, Pfizer, Regeneron, Sanofi Genzyme, Trialspark, and UCB. Jinan Liu and Daniel Sturm are employees and shareholders of Incyte Corporation. Simran Marwaha, James Piercy, and Peter Anderson are employees of Adelphi Real World.
: The Disease Specific Programme (DSP) fulfills the definition of a market research survey under the EphRMA Code of Conduct and is therefore conducted to market research, rather than clinical, guidelines. Market research surveys are exempt from requiring institutional review board (IRB) approval; however, the Pearl IRB conducted a methodologic review of the atopic dermatitis DSP and provided an exemption (reference AG9174). Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act of 1996 and Health Information Technology for Economic and Clinical Health Act legislation. In addition, the DSP was conducted in compliance with the International Council for Harmonisation Declaration of Helsinki. Freely given, specific, and informed consent was obtained from each respondent to take part in the DSP and for the processing of their personal data. All data provided by physicians and patients were anonymized.